National Evaluation of the Adherence to Recommendations of Venous Thrombo Embolism Treatment in Cancer Patients
NCT ID: NCT01362933
Last Updated: 2015-03-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
502 participants
OBSERVATIONAL
2011-05-31
2012-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cancer-related Thromboembolic Disease
NCT02785757
Anti Xa Activity in Cancer Patients Receiving Low-molecular-weight Heparin for Venous Thromboembolism
NCT02898051
Prescription and Utilization of Low Molecular Weight Heparin in Usual Medical Practice for the Curative Treatment of Venous Thromboembolism in Patients With Cancer
NCT01803022
Prophylaxis of Thrombosis With Implantable Devices for Central Venous Access in Cancer Patients
NCT00199602
Implementing VTE Prevention in Ambulatory Cancer Care
NCT07292376
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
VTE treatment in cancer patient
All patients with cancer present in the clinic, hospital, out patient diagnosed with a VTE during the 6 previous months.
VTE treatment in cancer patient description
proportion of patients treated for evolutive VTE according to international recommendations
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
VTE treatment in cancer patient description
proportion of patients treated for evolutive VTE according to international recommendations
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patient refusing the study
* Patient under 18 and/or not competent to give informed consent
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Universitaire, Amiens
OTHER
Groupe Francophone Thrombose et Cancer (GFTC)
UNKNOWN
University Hospital, Grenoble
OTHER
Floralis
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Marie-Antoinette SEVESTRE, MD
Role: PRINCIPAL_INVESTIGATOR
Centre Hospitalier Universitaire, Amiens
Dominique FARGE BANCEL, MD
Role: STUDY_DIRECTOR
GFTC
Jean Luc BOSSON, MD
Role: STUDY_DIRECTOR
University Hospital, Grenoble
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHR Annecy
Annecy, , France
Centre Hospitalier Victor Dupouy
Argenteuil, , France
CH AUCH
Auch, , France
CH Beauvais
Beauvais, , France
Institut Bergonie
Bordeaux, , France
CHU de Brest
Brest, , France
CHU de Caen
Caen, , France
Centre François Baclesse
Caen, , France
CH Antoine Gayraud Cedex 9
Carcassonne, , France
Clinique du Parc CASTELNAU LE LEZ
Castelnau-le-Lez, , France
Pôle Santé Léonard de Vinci
Chambray-lès-Tours, , France
CH Chalons En Champagne
Châlons-en-Champagne, , France
Centre Jean Perrin Clcc
Clermont-Ferrand, , France
CHU
Clermont-Ferrand, , France
Hopital Louis Mourier Colombes
Colombes, , France
Polyclinique Saint come
Compiègne, , France
CHU Bocage Dijon
Dijon, , France
CHU
Grenoble, , France
Ch Versailles Andre Maginot
Le Chesnay, , France
CHRU Calmette
Lille, , France
CHRU LILLE, Hôpital Huriez
Lille, , France
CHRU Albert Calmette
Lille, , France
Centre Hospitalier Edouard Herriot
Lyon, , France
Hopital Desgenettes LYON
Lyon, , France
Centre Leon Berard LYON
Lyon, , France
CH Saint Joseph Saint Luc
Lyon, , France
Institut Paoli Calmette Marseille
Marseille, , France
Hopital Saint Joseph
Marseille, , France
CHU La Timone Marseille
Marseille, , France
Hôpital Nord Marseille
Marseille, , France
Centre Régional de Lutte Contre le Cancer Val d'Aurelle
Montpellier, , France
CHU Hôtel-Dieu NANTES
Nantes, , France
Centre de Lutte contre le Cancer (Centre René Gauducheau)
Nantes, , France
CHR Orleans
Orléans, , France
Hopital Saint Louis Paris
Paris, , France
Hopital Saint Antoine Paris
Paris, , France
Hopital de la Salpetriere Paris
Paris, , France
Hopital Val de GRACE
Paris, , France
Hôpital Kremlin Bicêtre
Paris, , France
CH Lyon Sud
Pierre-Bénite, , France
CHU Rouen
Rouen, , France
Centre Rene Hugunin institut curie
Saint-Cloud, , France
Centre Hospitalier Mutualiste Site Etienne Dolet
Saint-Nazaire, , France
Clinique Charcot,
Sainte-Foy-lès-Lyon, , France
CHRU Strasbourg
Strasbourg, , France
CH Valence
Valence, , France
Ch Bretagne Atlantique
Vannes, , France
Centre Hospitalier de Villefranche sur Saône
Villefranche-sur-Saône, , France
Institut Gustave Roussy
Villejuif, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer. 2007 Nov 15;110(10):2339-46. doi: 10.1002/cncr.23062.
Levitan N, Dowlati A, Remick SC, Tahsildar HI, Sivinski LD, Beyth R, Rimm AA. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore). 1999 Sep;78(5):285-91. doi: 10.1097/00005792-199909000-00001.
Khorana AA, Francis CW, Culakova E, Lyman GH. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer. 2005 Dec 15;104(12):2822-9. doi: 10.1002/cncr.21496.
Blom JW, Vanderschoot JP, Oostindier MJ, Osanto S, van der Meer FJ, Rosendaal FR. Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J Thromb Haemost. 2006 Mar;4(3):529-35. doi: 10.1111/j.1538-7836.2006.01804.x.
Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006 Feb 27;166(4):458-64. doi: 10.1001/archinte.166.4.458.
Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ 3rd. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000 Mar 27;160(6):809-15. doi: 10.1001/archinte.160.6.809.
Lee AY, Levine MN, Butler G, Webb C, Costantini L, Gu C, Julian JA. Incidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancer. J Clin Oncol. 2006 Mar 20;24(9):1404-8. doi: 10.1200/JCO.2005.03.5600.
Related Links
Access external resources that provide additional context or updates about the study.
American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Version N°2.0 du 21/03/2011
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.